- $315.99m
- $1.24bn
- $0.89m
BofA downgrades ProKidney on concerns about experimental kidney disease treatment
Brief: ProKidney Q1 Operating Income USD -41.388 Million
ProKidney Corp reports results for the quarter ended December 31 - Earnings Summary
ProKidney Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: ProKidney Q3 Operating Income USD -48.973 Million Vs. IBES Estimate USD -44.3 Million
ProKidney Corp expected to post a loss of 15 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Estée Lauder, Quanta Services
Brief: Prokidney Announces Strategic Updates To Its Phase 3 Program To Accelerate Rilparencel’S Registrational Path To Potential Approval In The U.S.
ProKidney Corp reports results for the quarter ended in June - Earnings Summary
Brief: ProKidney Q2 Operating Income USD -43.056 Million
ProKidney Corp expected to post a loss of 17 cents a share - Earnings Preview
Brief: ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares
U.S. STOCKS ON THE MOVE-Tesla, Casey's General Store, Western Alliance
U.S. STOCKS ON THE MOVE-Tesla, Take-Two, Caterpillar
U.S. STOCKS ON THE MOVE-Oracle, Beamr Imaging, Casey's General Stores
ProKidney rebounds after upsized $130 mln equity raise
ProKidney ticks lower after upsized $130 mln equity raise
Brief: Prokidney Says Pricing Of 53.7 Mln Shares at $2.42 Per Share
U.S. RESEARCH ROUNDUP-Biomea Fusion, Enphase Energy, Perion Network